

**MYCN Antibody (C-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP7395b****Specification**

---

**MYCN Antibody (C-term) Blocking Peptide - Product Information**Primary Accession [P04198](#)**MYCN Antibody (C-term) Blocking Peptide - Additional Information****Gene ID** 4613**Other Names**

N-myc proto-oncogene protein, Class E basic helix-loop-helix protein 37, bHLHe37, MYCN, BHLHE37, NMYC

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP7395b](/products/AP7395b) was selected from the C-term region of human MYCN. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**MYCN Antibody (C-term) Blocking Peptide - Protein Information****Name** MYCN**Synonyms** BHLHE37, NMYC**Function**

Positively regulates the transcription of MYCNOS in neuroblastoma cells.

**Cellular Location**

Nucleus.

**Tissue Location**

Expressed in the neuronal cells of the cerebrum, neuroblastomas and thyroid tumors (at protein level)

## **MYCN Antibody (C-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

## **MYCN Antibody (C-term) Blocking Peptide - Images**

## **MYCN Antibody (C-term) Blocking Peptide - Background**

MYCN is a member of the MYC family and a protein with a basic helix-loop-helix (bHLH) domain. This protein is located in the nucleus and must dimerize with another bHLH protein in order to bind DNA. Amplification of its gene is associated with a variety of tumors, most notably neuroblastomas.

## **MYCN Antibody (C-term) Blocking Peptide - References**

Combaret,V., Pediatr Blood Cancer 53 (3), 329-331 (2009)Alvarez-Rodriguez,R., J. Cell. Sci. 122 (PT 5), 595-599 (2009)Jacobs,J.F., BMC Cancer 9, 239 (2009)